NCT06625775 2026-03-18
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1 Recruiting
Clinical Trials
22 trialsNCT06917079 2026-03-18
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1 Recruiting
NCT04808323 2026-03-16
MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer
Medical College of Wisconsin
Phase 1 Recruiting
NCT06179160 2026-03-16
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Incyte Corporation
Phase 1 Recruiting
NCT06663319 2026-03-13
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT05733689 2026-03-10
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
University of California, Irvine
Phase 1 Recruiting
NCT04929223 2026-03-03
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Hoffmann-La Roche
Phase 1 Recruiting
NCT06838338 2026-01-08
JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC
Peking University Cancer Hospital & Institute
Phase 1 Active not recruiting
NCT00059930 2025-03-26
Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT06833866 2025-02-19
Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer
The Methodist Hospital Research Institute
Phase 1 Recruiting
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT05912075 2024-02-08
PRAAR1
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Recruiting
NCT01420874 2023-05-06
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
Barbara Ann Karmanos Cancer Institute
Phase 1 Completed
NCT00851136 2022-12-13
A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)
Genentech, Inc.
Phase 1 Completed
NCT04991948 2022-03-09
Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
Celyad Oncology SA
Phase 1 Recruiting
NCT03760614 2021-01-15
A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma
Abramson Cancer Center at Penn Medicine
Phase 1 Withdrawn
NCT03035253 2020-08-11
A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer
Mereo BioPharma
Phase 1 Terminated
NCT02069041 2018-11-21
A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00873756 2016-11-02
A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
Genentech, Inc.
Phase 1 Completed
NCT00599924 2015-07-15
Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
Pfizer
Phase 1 Completed
NCT00008294 2013-01-18
Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00101894 2012-09-17
Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer
Amgen
Phase 1 Completed